Soleno Therapeutics (SLNO) Amortization of Deferred Charges (2014 - 2026)
Soleno Therapeutics (SLNO) reported Amortization of Deferred Charges of $8000.0 for Q1 2026, little changed year-over-year from $8000.0 in Q1 2025, and down 11.11% quarter-over-quarter from $9000.0 in Q4 2025.
Soleno Therapeutics (SLNO) Amortization of Deferred Charges (2014 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 3 years of Amortization of Deferred Charges data on file, last reported at $8000.0 in Q1 2026.
- Amortization of Deferred Charges for Q1 2026 came in at $8000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $35000.0 (down 98.08% YoY), and the FY2025 annual result was $35000.0, changed N/A from the prior year.
- Amortization of Deferred Charges fell to $8000.0 in Q1 2026 per SLNO's latest filing, from $9000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $9000.0 in Q2 2025 and troughed at $8000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8,000.00 |
| Mar 31, 2026 | 8,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Sep 30, 2025 | 9,000.00 |
| Sep 30, 2025 | 9,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Sep 30, 2014 | 753,000.00 |
| Sep 30, 2014 | 753,000.00 |
| Jun 30, 2014 | 670,000.00 |
| Jun 30, 2014 | 670,000.00 |
| Mar 31, 2014 | 388,000.00 |
| Mar 31, 2014 | 388,000.00 |